Common questions about Клайра (FAQ)
Q: Can women over the age of 35 safely use Клайра?
Official regulatory documents generally list the medicine as contraindicated for women 35 years of age or older who smoke. This constraint is due to a substantially increased risk of serious cardiovascular events in this specific group. Official documents do not list age alone as a reason to prohibit use.
Q: What are the general signs of a serious but rare side effect associated with Клайра?
Patient safety warnings, according to regulatory sources, highlight signs of serious blood clots (Thromboembolic Events). These signs can include sudden unexplained breathlessness, sharp chest pain, sudden severe headache, or sudden trouble speaking or walking. Pain or swelling in the leg is also a potential sign to be aware of.
Q: How does the body process the hormones in Клайра?
Клайра contains estradiol valerate, which the body processes as a prodrug and converts into 17beta-estradiol, a natural estrogen. The progestin component, dienogest, is metabolized with the involvement of a liver enzyme system known as CYP3A4. This process allows the body to absorb and use the active ingredients.
Q: Is it normal to have a very light period, or no period, while using Клайра?
Yes, official product information and clinical trial data indicate that a very light period or no periods (amenorrhoea) is a common reported side effect. Studies have also documented a significant reduction in menstrual blood loss volume for users of this medicine.
Q: Can certain anti-seizure medications interfere with the effectiveness of Клайра?
Official documents state that medicines that induce CYP3A4 enzymes may decrease the concentration of hormones in the blood, potentially reducing the medicine's effectiveness. This group often includes specific anti-epileptic or anti-seizure agents.
Q: Is there official information available on the long-term safety of using Клайра for many years?
Official documentation notes that the risk of blood clots (VTE) is highest during the first year of use or upon restarting after a four-week break. While risk patterns are documented to change over time, the regulatory text does not contain a specific statement summarizing safety after many years of continuous use.
Q: What should a user generally expect regarding their monthly cycle while taking Клайра?
The expected pattern is that withdrawal bleeding typically starts during the intake of the last active or inactive tablets of the pack. It is common for this bleeding not to be finished before the next 28-day pack is started. Experiencing no periods or irregular bleeding is also commonly reported.
Q: How is Клайра different from other combined oral contraceptives?
According to the official product description, the key differences relate to its composition and dosing structure. The medicine utilizes a dynamic-dose, four-phasic regimen, meaning the hormone levels vary across the cycle. Additionally, it contains the natural estrogen precursor estradiol valerate.
Q: How quickly does Клайра start to prevent pregnancy?
Official guidance on starting the medicine suggests that when switching from certain other methods or starting late, an additional barrier method of contraception is advised. This barrier method is advised for the first 9 consecutive days of taking the active pills.
Q: Do common antibiotics reduce the effectiveness of Клайра?
Regulatory text cites a potential risk of reduced effectiveness only with CYP3A4-inducing anti-infective agents, such as Rifampicin. Most common broad-spectrum antibiotics (such as those prescribed for minor infections) are typically not cited as a major risk in the official drug interaction documents.
Q: What happens if a non-active (white) pill is forgotten or missed?
If a non-active (white) tablet is missed, official instructions state that the tablet is advised to be discarded. Protection against pregnancy is not reduced by missing an inactive tablet, and the user is advised to simply continue taking the remaining tablets as scheduled.
Q: Is hair loss or hair thinning a reported side effect of Клайра?
Yes, official regulatory documentation lists hair thinning, or alopecia, as an uncommon side effect. Side effects are categorized based on how frequently they were reported in clinical studies.
Q: Does a history of migraines affect eligibility for using Клайра?
According to the official prescribing information, a history of migraine with aura is listed as a condition that contraindicates the use of this medicine.
Q: Does using Клайра affect cholesterol levels?
Official safety information for combined hormonal contraceptives includes warnings that these medicines may cause changes in serum lipid (cholesterol) levels. Changes in these levels are described as a general consideration when assessing combined hormonal contraceptives.
